(Q40634755)

22 September 2017

title

Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial (English)

1 reference

22 September 2017

0 references

1 reference

1 reference

D I Bernstein

1

1 reference

22 September 2017

D A Sack

2

1 reference

22 September 2017

E Rothstein

3

1 reference

22 September 2017

K Reisinger

4

1 reference

22 September 2017

V E Smith

5

1 reference

22 September 2017

D O'Sullivan

6

1 reference

22 September 2017

D R Spriggs

7

1 reference

22 September 2017

R L Ward

8

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 July 1999

1 reference

22 September 2017

1 reference

22 September 2017

volume

354

1 reference

22 September 2017

issue

9175

1 reference

22 September 2017

page(s)

287-290

1 reference

Cost-effectiveness analysis of a rotavirus immunization program for the United States

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912106-2

7 January 2021

Rotavirus vaccines at the threshold

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912106-2

7 January 2021

Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912106-2

7 January 2021

Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912106-2

7 January 2021

Rotavirus infection in infants as protection against subsequent infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912106-2

7 January 2021

Protection against Rotavirus Disease after Natural Rotavirus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912106-2

7 January 2021

Mechanisms of protection against rotavirus in humans and mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912106-2

7 January 2021

Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912106-2

7 January 2021

Protection from Rotavirus Reinfection: 2-Year Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912106-2

7 January 2021

Development of an improved method for measuring neutralizing antibody to rotavirus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912106-2

7 January 2021

The Protective Effectiveness of Natural Rotavirus Infection in an American Indian Population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912106-2

7 January 2021

Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2912106-2

7 January 2021

10.1016/S0140-6736(98)12106-2

Identifiers

DOI

1 reference

22 September 2017

1 reference